{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:49:32Z","timestamp":1788871772837,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.leukres.2009.11.002","type":"journal-article","created":{"date-parts":[[2009,12,6]],"date-time":"2009-12-06T19:11:51Z","timestamp":1260126711000},"page":"827-829","source":"Crossref","is-referenced-by-count":30,"title":["Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec\u2122)"],"prefix":"10.1016","volume":"34","author":[{"given":"Jessica K.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Magid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fleisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellin","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.11.002_bib1","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.11.002_bib2","unstructured":"http:\/\/www.gleevec.com\/index.jsp [homepage on the internet]. Novartis Pharmaceuticals Corporation; c2008 [cited 2009 Oct 11]. Prescribing information at: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gleevec_tabs.pdf."},{"key":"10.1016\/j.leukres.2009.11.002_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3324\/haematol.11680","article-title":"Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib","volume":"93","author":"Franceschino","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.11.002_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.leu.2402868","article-title":"Intramuscular edema as a complication of treatment with imatinib","volume":"17","author":"Shimazaki","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.11.002_bib5","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1056\/NEJMc0708896","article-title":"Imatinib as a possible cause of severe rhabdomyolysis","volume":"358","author":"Penel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.11.002_bib6","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.leukres.2009.11.002_bib7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/bdrc.10030","article-title":"Biology of platelet-derived growth factors in development","volume":"69","author":"Betsholtz","year":"2003","journal-title":"Birth Defects Res (Part C)"},{"key":"10.1016\/j.leukres.2009.11.002_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.1414","article-title":"Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study","volume":"201","author":"Zhao","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.leukres.2009.11.002_bib9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.leukres.2009.11.002_bib10","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1096\/fj.09-129833","article-title":"Imatinib attenuates skeletal muscle dystrophy in mdx mice","volume":"23","author":"Huang","year":"2009","journal-title":"FASEB J"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609005244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609005244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T15:21:13Z","timestamp":1544800873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609005244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0145212609005244"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.11.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}